Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia

Sheba Medical Center

Status and phase

Unknown

Phase 2

Conditions

Schizophrenia

Schizoaffective Disorder

Treatments

Drug: D-serine

Study type

Interventional

Funder types

Other

Identifiers

NCT00138775

SHEBA-03-3093-MW-CTIL

Details and patient eligibility

About

The goal of the present study is to evaluate the effect of D-serine, added to antipsychotic treatment, on negative and cognitive symptoms in schizophrenia.

The investigators are hypothesizing that D-serine will improve cognitive functioning and negative symptoms.

Sex

All

Ages

18 to 64 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnostic and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV) diagnosis of schizophrenia and\or schizoaffective disorder.
Age between 18 to 64.
PANSS negative symptom score higher than 19.
SAS total score lower than 12.
CDSS suicidal risk lower than 2

Exclusion criteria

Epilepsy
Meets DSM-IV criteria for mental retardation.
Medical condition which confounds presentation or treatment (e.g. uncontrolled diabetes mellitus, history of kidney stones, acute drug toxicity, dementia, delirium, stroke, etc.)
Meets DSM-IV criteria for alcohol or drug dependence in last 6 months.
Meets DSM-IV criteria for alcohol or drug abuse in last one month.
Treatment with clozapine.
Current positive pregnancy test or not using acceptable method of birth control.
Meets DSM-IV criteria for current anxiety or mood disorders